AMEX Biotech Stock
Samaritan Pharmaceuticals, Inc. (the "Company", "Samaritan", or "Registrant") is working to ensure a longer and better life for patients suffering with AIDS, Alzheimer's, cancer, and cardiovascular disease. Samaritan is a pipeline-driven biopharmaceutical company, with a clear focus on advancing early stage innovative drugs through clinical development, to become commercially valuable ...
more
To date, we have chosen to license products developed with our technology to other drug companies. We intend to pursue additional strategic alliances, as well as to consider fully developing and commercializing product candidates internally.
more
We are a biotechnology company engaged in the research, development, and commercialization of patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes. Patented islet transplantation technology, exclusively licensed from Duke University, along with our own developments, constitute methods for isolating, culturing, cryopreservation, and ...
more
We are a biopharmaceutical company focused on the development of drugs to treat relapsed acute leukemia, multiple myeloma (an incurable blood cancer that invades and proliferates in bone marrow), other cancers and osteolytic bone disease. Our lead drug candidate, Annamycin, a drug from the anthracycline family, earlier completed a Phase I/IIa trial in refractory leukemia ...
more
This description contains
certain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from the results discussed in the forward-looking statements as a result of certain of the risks set forth herein and elsewhere in
this Form 10-KSB. We assume no obligation to update any forward-looking statements contained herein.
more
Celsion Corporation engages in the research and development of health treatment systems for the cure of cancer and other diseases.
more
EPI was incorporated in the State of Delaware on October 1, 1997. EPI's predecessor, Prologica International, Inc. ("Prologica"), was incorporated in the State of Pennsylvania on April 20, 1984. From the time of its incorporation, and the completion of its initial public offering in August 1998, until the date of its merger with EPI, Prologica engaged in no business other than searching for ...
more
RegeneRx Biopharmaceuticals, Inc. (the “Company”, “We”, “Us”, “Our”), is a biopharmaceutical company focused on the discovery and development of novel molecules to accelerate
tissue and organ repair. Currently, we are developing Thymosin beta 4 (“Tß4 ” ), a 43 amino acid
peptide. Current research suggests that Tß4 may prove ...
more
The primary
business of Senesco Technologies, Inc., a Delaware corporation
incorporated in 1999, and its wholly-owned subsidiary, Senesco, Inc., a
New Jersey corporation incorporated in 1998, collectively referred to as “Senesco,”
“we,” “us” or “our,” is the research, development and commercial exploitation
of a potentially significant platform ...
more
We are in the
business of developing, manufacturing, and marketing proprietary products used
in the site-specific, non-invasive administration of soluble salts or other
drugs into the body for medical purposes.
Our active drug delivery systems employ iontophoresis (explained more
fully below) as a non-invasive method of enhancing and controlling the
transport of water-soluble ionic drugs ...
more
Daxor Corporation is a
medical device manufacturing company with additional biotechnology services.
Daxor was originally founded in 1970 for cryobanking services and continues
these services through its wholly owned subsidiary, Scientific Medical Systems.
For the past 11 years, the Company’s major focus has been on the development of
the BVA-100® Blood Volume Analyzer, an instrument ...
more
IGI, Inc. ("IGI" or the "Company") was incorporated in Delaware in 1977. Its executive offices are at 105 Lincoln Avenue, Buena, New Jersey. The Company is principally engaged in the manufacturing of cosmetics, skin care, and consumer products for third parties utilizing Novasome® lipid vesicle encapsulation and other technologies and intends to launch ...
more
We are a theranostics (therapy and diagnosis) company, involved in both the detection and
treatment of cancer. While in the recent past most of our sales have been derived from the sale of
one of our OEM products, the Company’s long term potential and prospects will come from its
proprietary product DR-70® and from its combination immunogene therapy ...
more
Today, Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics. Each operates in both the United States and international markets. For a description of business and financial information on industry and geographic segments, see Note 15 on pages 28 through 31 of Exhibit 13.1, which is incorporated herein by reference.
more
Today, Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics. Each operates in both the United States and international markets. For a description of business and financial information on industry and geographic segments, see Note 15 on pages 28 through 31 of Exhibit 13.1, which is incorporated herein by reference.
more
